Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 1, 2007, Pages 344-353

  Othman, Ahmed A ^a   Syed, Shariq A ^a   Newman, Amy H ^b   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' CHLORO 3ALPHA (DIPHENYLMETHOXY)TROPANE; 4',4' DICHLORO 3ALPHA (DIPHENYLMETHOXY)TROPANE; BENZATROPINE; COCAINE; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG ABUSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEADY STATE;

ANIMALS; BENZTROPINE; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE; COCAINE-RELATED DISORDERS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MALE; MICROSOMES, LIVER; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 33845909632     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.111245     Document Type: Article

References (31)

1. Armstrong SC and Schweitzer SM (1997) Delirium associated with paroxetine and benztropine combination. Am J Psychiatry 154:581-582.
2. Carroll FI, Howell LL, and Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42:2721-2736.
3. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, and Katz JL (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893.
4. Gorelick DA (1998) The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 42:995-997.
5. He H, McKay G, and Midha KK (1995) Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica 25:857-872.
6. Katz JL, Agoston GE, Alling KL, Kline RH, Forster MJ, Woolverton WL, Kopajtic TA, and Newman AH (2001) Dopamine transporter binding without cocaine-like behavioral effects: synthesis and evaluation of benztropine analogs alone and in combination with cocaine in rodents. Psychopharmacology (Berl) 154:362-374.
7. Katz JL, Izenwasser S, Kline RH, Allen AC, and Newman AH (1999) Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288:302-315.
8. Katz JL, Kopajtic TA, Agoston GE, and Newman AH (2004) Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309:650-660.
9. Kline RH, Izenwasser S, Katz JL, Joseph DB, Bowen WD, and Newman AH (1997) 3′-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4′-chloro-3 alpha-(diphenylmethoxy) tropane produces a cocaine-like behavioral profile. J Med Chem 40:851-857.
10. Kulkarni SS, Grundt P, Kopajtic T, Katz JL, and Newman AH (2004) Structureactivity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation. J Med Chem 47:3388-3398.
11. SM, Newman AH, and Katz JL (2005) Place conditioning and locomotor effects of N-substituted, 4′,4″-difluorobenztropine analogs in rats. J Pharmacol Exp Ther 313:1223-1230.
12. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
13. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324.
14. Newman AH, Allen AC, Izenwasser S, and Katz JL (1994) Novel 3 alpha-(diphenylmethoxy)tropane analogs: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J Med Chem 37:2258-2261.
15. Newman AH, Kline RH, Allen AC, Izenwasser S, George C, and Katz JL (1995) Novel 4′-substituted and 4′,4″-disubstituted 3 alpha-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J Med Chem 38:3933-3940.
16. Newman AH and Kulkarni S (2002) Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic - a focus on analogues of benztropine and rimcazole. Med Res Rev 22:429-464.
17. Quinn DI, Wodak A, and Day RO (1997) Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet 33:344-400.
18. Raje S, Cao J, Newman AH, Gao H, and Eddington ND (2003) Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307:801-808.
19. Raje S, Dowling TC, and Eddington ND (2002) Determination of the benztropine analog AHN-1055, a dopamine uptake inhibitor, in rat plasma and brain by high-performance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 768:305-313.
20. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
21. Roth A, Akyol S, and Nelson JC (1994) Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 55:492-495.
22. Rothman RB (1990) High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sci 46:PL17-PL21.
23. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313:1361-1369.
24. Sheiner LB and Ludden TM (1992) Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 32:185-209.
25. Tanda G, Ebbs A, Newman AH, and Katz JL (2005) Effects of 4′-chloro-3{alpha}-(diphenylmethoxy)-tropane on mesostriatal, mesocortical, and mesolimbic dopamine transmission: comparison with effects of cocaine. J Pharmacol Exp Ther 313:613-620.
26. Taub ME, Podila L, Ely D, and Almeida I (2005) Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos 33:1679-1687.
27. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, et al. (1997) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (Lond) 386:827-830.
28. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
29. Woolverton WL, Hecht GS, Agoston GE, Katz JL, and Newman AH (2001) Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology (Berl) 154:375-382.
30. Woolverton WL, Rowlett JK, Wilcox KM, Paul IA, Kline RH, Newman AH, and Katz JL (2000) 3′- and 4′-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys. Psychopharmacology (Berl) 147:426-435.
31. Zou MF, Kopajtic T, Katz JL, and Newman AH (2003) Structure-activity relationship comparison of (S)-2beta-substituted 3alpha-(bis[4- fluorophenyl]methoxy)tropanes and (R)-2beta-substituted 3beta-(3,4- dichlorophenyl)tropanes at the dopamine transporter. J Med Chem 46:2908-2916.